*Olapatadine/mometasone furoate
Study Objective
To evaluate efficacy and safety of olopatadine mometasone combination Vs its individual components in Chinese SAR patients.
Results
Superior Nasal Symptom Relief Vs Monotherapies
The Olopatadine + Mometasone combination showed significant improvements in average 12-hour rTNSS from baseline to Day 14 compared to Olopatadine (OLO) and Mometasone Furoate (MF) alone (P < 0.0001).
Benefits were seen from Day 1 through Day 14, indicating a rapid onset with sustained relief.
Olopatadine + Mometasone combination significantly improved all individual reflective nasal symptoms during the 14-day treatment period (P < 0.05).
Figure 1: Change from baseline in average A.M. and P.M. subject-reported rTNSS for each day.
Better Ocular Symptom Relief
Olopatadine + Mometasone combination significantly improved average A.M. and P.M. rTOSS (reflective Total Ocular Symptom Score; P = 0.0335 vs OLO and P = 0.0004 vs MF)
Benefits were seen from Day 1 through Day 14, indicating a rapid onset with sustained relief.
Olopatadine + Mometasone combination significantly improved most reflective ocular symptoms vs monotherapies (P < 0.05).
Figure 2: Change from baseline in average A.M. and P.M. subject-reported rTOSS for each day.
Better Quality of Life
Significant improvement in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score at Day 15 was reported (P < 0.0001 vs OLO and P = 0.0058 vs MF).
Anti-Inflammatory Biomarker Benefits
Exploratory analysis showed that IL-5, ECP levels significantly reduced with Olopatadine + Mometasone combination.
Compared with Mometasone Furoate or Olopatadine monotherapy, Olopatadine + Mometasone combination demonstrated superior efficacy with favorable tolerability, delivering statistically significant and clinically meaningful improvements in patients with moderate-to-severe SAR.
Figure 3: (A) Concentrations of IL-5 at baseline and 14 days after the 3 treatments. (B) Concentrations of ECP at baseline and 14 days after the 3 treatments. (C) The percentage change in IL-5 levels between baseline and 14 days after treatment.
SAR: Seasonal Allergic Rhinitis; rTOSS: reflective total ocular symptom score; rTNSS: reflective total nasal symptom score; IL-5: Interleukin-5; ECP: eosinophilic cationic protein. Ref: Sima et al. World Allergy Organization Journal (2026) 19:101341. http://doi.org/10.1016/j.waojou.2026.101341.